Clinical Trials in Leicester, UK

Clinical Trials in Leicester

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Status

Study

Lead sponsor

Phase

Enrol

UK sites

Start

Not yet open

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology

Boehringer Ingelheim

Phase 1/2

Leicester, Newcastle upon Tyne

2026-09-29

Not yet open

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

NCT07540988Interstitial Lung Diseases

Boehringer Ingelheim

Phase 3

466

Birmingham, Exeter, Leeds, Leicester, London, Manchester, Oxford

2026-09-14

Active, closed

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

NCT07662122Obesity, Overweight

Boehringer Ingelheim

Phase 2

342

Blackpool, Guisborough, High Wycombe, Leicester, Middlesbrough, Oxford

2026-06-30

Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Boehringer Ingelheim

Phase 3

670

Cardiff, Leicester, Manchester, Sutton, Torquay

2026-04-13

Recruiting

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083Focal Segmental Glomerulosclerosis

Boehringer Ingelheim

Phase 3

286

Bebington, Bradford, Cambridge, Leicester, London, Salford

2026-02-16

Active, closed

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy

NCT05990738Small Cell Lung Carcinoma (SCLC)

Boehringer Ingelheim

Phase 1

Leicester

2024-02-14

Active, closed

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574Lung Cancer, Non-squamous, Non-small Cell

Boehringer Ingelheim

Phase 3

428

Edinburgh, Leicester, London, Sutton

2024-02-09

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma

Boehringer Ingelheim

Phase 2

204

Leicester, London, Manchester, Newcastle upon Tyne

2023-10-13

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/leicester

Query this register directly

GET /api/trials?country=uk&status=recruiting&format=json Try it now →